ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2025
Cystic fibrosis airway epithelial cells have an exaggerated response to hypoxia that is partially reversible through transmembrane receptor modulation.
Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The pathophysiology of cystic fibrosis (CF) leads to epithelial cell hypoxia, which directly affects epithelial cells. CF is caused by genetic disruption of the CF transmembrane receptor that has important direct impacts on cell signaling and proteotoxic stress, and indirect impacts through microbiome alterations. How these alterations impact hypoxia signaling is not known. We collected primary human airway cells from explanted lungs of individuals with or without CF, differentiated them at air-liquid interface, and subjected them to short-term hypoxia. Differential gene expression was assessed by RNAseq, with findings validated by flow cytometry. We also assessed the impacts of modulator therapies on CF epithelial cells. While there was overlap in the transcriptomic response to hypoxia between CF and referent epithelial cells, CF cells activated additional pathways. In CF cells under hypoxia, activation of the hypoxia pathway was associated with HIF1α, EMT, and immune-related pathways, the latter not seen in referent cells. Among HIF1α related genes, VEGF was uniquely increased in cells from CF, and its expression was modulated through HIF1α signaling. We show that correction of CFTR blunts exaggerated response to hypoxia in CF cells. These results suggest CF airway cells have an exacerbated response to hypoxia, which may be alleviated through the correction of misfolded CFTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.